Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer

NCT02967770 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Issues with patient recruitment.

Conditions

Metastatic Pancreatic Cancer

Interventions

OTHER: Molecularly Tailored Second Line Therapy
DRUG: Standard of Care Second Line Therapy

Sponsor

Georgetown University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]